Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Am J Hematol. 2016 Aug 8;91(11):1090–1095. doi: 10.1002/ajh.24493

Figure 3.

Figure 3

(A) TTFT of Rai stage 0-II patients (Mayo clinic cohort) based on the original CLL-IPI: Low-risk (CLL-IPI score 0–1); Intermediate-risk (CLL-IPI score 2–3); High-risk (CLL-IPI score ≥ 4).

(B) TTFT of Rai stage 0-II patients (Mayo clinic cohort) based on the revised CLL-IPI: The CLL-IPI risk categories were the following: Low-risk (CLL-IPI score 0); Intermediate-risk (CLL-IPI score 1); High-risk (CLL-IPI score ≥ 2).